Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

278.45
-1.1500-0.41%
Volume:8.04K
Turnover:2.24M
Market Cap:6.18B
PE:-15.50
High:281.03
Open:281.03
Low:275.00
Close:279.60
Loading ...

BRIEF-Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq listing rule

Reuters
·
15 hours ago

Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial

Reuters
·
13 May

BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis

Reuters
·
10 May

Madrigal Pharmaceuticals Inc - Patients Achieved 6.7 Kpa Reduction in Liver Stiffness

THOMSON REUTERS
·
10 May

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (Resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients With Compensated Mash Cirrhosis

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals Inc - Rezdiffra Well-Tolerated With Low Discontinuation Rate

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals: 65% of Patients With Clinically Significant Portal Hypertension at Baseline Moved Into Lower Risk Categories by Year Two

THOMSON REUTERS
·
10 May

Madrigal Pharmaceuticals Is Maintained at Buy by UBS

Dow Jones
·
03 May

Madrigal Pharmaceuticals Price Target Raised to $460.00/Share From $422.00 by B. Riley Securities

Dow Jones
·
03 May

Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
02 May

UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating

MT Newswires Live
·
02 May

Madrigal Pharmaceuticals Reports Strong Q1 2025 Results

TIPRANKS
·
02 May

Q1 2025 Madrigal Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
02 May

Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating

TIPRANKS
·
02 May

Stock Track | Madrigal Pharmaceuticals Plummets 5.59% Despite Beating Q1 Earnings Estimates

Stock Track
·
01 May

Madrigal Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
01 May

Madrigal Pharmaceuticals Q1 Loss Narrows

MT Newswires Live
·
01 May

Madrigal: Q1 Earnings Snapshot

Associated Press Finance
·
01 May

Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Revenue $137.3M, vs. FactSet Est of $114.7M

MT Newswires Live
·
01 May

Madrigal Pharmaceuticals Reports Q1 2025: Rezdiffra Sales Reach $137.3M; Positive Feedback from Healthcare Providers

Reuters
·
01 May